.START 

REPLIGEN Inc. said it will issue one million new common shares in a $9 million private placement to institutional investors in the U.K.
The Cambridge, Mass., biotechnology company said proceeds will be used to broaden its research and development of products to fight infectious diseases and to increase manufacturing capabilities.
Bear Stearns & Co. handled the closing of the transactions, Repligen said.
After the sale, Repligen will have about 8.3 million shares outstanding. 

